癸基泛醌通过上调沉默调节蛋白2抑制结直肠癌生长。
Decylubiquinone Inhibits Colorectal Cancer Growth Through Upregulating Sirtuin2.
作者信息
Li Jinlian, Zheng Shuting, Cheng Ting, Li Yuanyuan, Mai Xiaobin, Jiang Guangchun, Yang Yongxia, Zhang Qianqian, Li Jiangchao, Zheng Lingyun, Wang Lijing, Qi Cuiling
机构信息
Institute of Basic Medical Sciences, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
出版信息
Front Pharmacol. 2022 Feb 1;12:804265. doi: 10.3389/fphar.2021.804265. eCollection 2021.
Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Decylubiquinone (DUb), a coenzyme Q10 analog, was reported to inhibit breast cancer growth and metastasis by us. However, the influence of DUb on CRC remains unclear. Herein, we found that DUb significantly inhibited CRC growth in the patient-derived xenograft (PDX) and CT26 xenograft models. DUb was further identified to significantly suppress CRC cell proliferation, colony formation, migration and invasion in a dose-dependent manner, while not inhibiting CRC cell apoptosis from flow cytometry assay. Sirtuin2 (SIRT2), a member of the sirtuin protein family, plays a critical role in growth and metastasis in various cancers. Moreover, DUb inhibited CRC progression by upregulating SIRT2. These findings reveal that DUb has the potential to a novel drug for the treatment of CRC by inhibiting CRC cell proliferation.
结直肠癌（CRC）是全球癌症相关死亡的主要原因之一。癸基泛醌（DUb）是一种辅酶Q10类似物，我们曾报道其可抑制乳腺癌的生长和转移。然而，DUb对结直肠癌的影响仍不清楚。在此，我们发现DUb在患者来源的异种移植（PDX）和CT26异种移植模型中显著抑制结直肠癌的生长。进一步确定DUb以剂量依赖的方式显著抑制结直肠癌细胞的增殖、集落形成、迁移和侵袭，而流式细胞术检测显示其不抑制结直肠癌细胞凋亡。沉默调节蛋白2（SIRT2）是沉默调节蛋白家族的成员之一，在多种癌症的生长和转移中起关键作用。此外，DUb通过上调SIRT2抑制结直肠癌进展。这些发现表明，DUb有潜力成为一种通过抑制结直肠癌细胞增殖来治疗结直肠癌的新型药物。
Zotero 插件